Cargando…

FLT3 mutational status is an independent risk factor for adverse outcomes after allogeneic transplantation in AML

Allogeneic HCT has been increasingly used in the setting of FLT3 mutated AML. However, its role in conferring durable relapse-free intervals remains in question. Herein, we sought to investigate FLT3 mutational status on transplant outcomes. We conducted a retrospective cohort study of 262 consecuti...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Yeohan, Magenau, John, Li, Yumeng, Braun, Thomas, Chang, Lawrence, Bixby, Dale, Hanauer, David A., Chughtai, Komal A., Gatza, Erin, Couriel, Daniel, Goldstein, Steven, Pawarode, Attaphol, Reddy, Pavan, Riwes, Mary, Connelly, James, Harris, Andrew, Kitko, Carrie, Levine, John, Yanik, Greg, Parkin, Brian, Choi, Sung Won
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4720584/
https://www.ncbi.nlm.nih.gov/pubmed/26191952
http://dx.doi.org/10.1038/bmt.2015.170
Descripción
Sumario:Allogeneic HCT has been increasingly used in the setting of FLT3 mutated AML. However, its role in conferring durable relapse-free intervals remains in question. Herein, we sought to investigate FLT3 mutational status on transplant outcomes. We conducted a retrospective cohort study of 262 consecutive AML patients who underwent first-time allogeneic HCT (2008-2014), of whom 171 had undergone FLT3-ITD mutational testing. FLT3 mutated AML was associated with nearly twice the relapse risk (RR) compared with those without FLT3 mutation 3 years post-HCT (63% vs. 37%, P<0.001), and with a shorter median time to relapse (100 vs. 121 days). FLT3 mutational status remained significantly associated with this outcome after controlling for patient, disease, and transplant-related risk factors (P<0.05). Multivariate analysis showed a significant association of FLT3 mutation with increased 3-year RR (HR 3.63, 95% CI: 2.13, 6.19, P<0.001), and inferior disease-free survival (HR 2.05, 95% CI: 1.29, 3.27, P<0.01) and overall survival (HR 1.92, 95% CI: 1.14, 3.24, P<0.05). These data demonstrate high risk of early relapse after allogeneic HCT for FLT3 mutated AML that translates into adverse disease-free and overall survival outcomes. Additional targeted and coordinated interventions are needed to maintain durable remission after allogeneic HCT in this high-risk population.